Transdermal delivery system containing rotigotine

US11633367B2 · kind B2 · utility

Assignee

• LTS Lohmann Therapie-Systeme AG · DE

Inventors

• Marco Emgenbroich · Neuss, DE
• Elke Klein · Bad Neuenahr-Ahrweiler, DE
• Heike Kluth · Ochtendung, DE

Key dates

• Filing date: May 20, 2015
• Grant date: Apr 25, 2023
• Expiry date: May 20, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A transdermal therapeutic system containing rotigotine base in a self-adhesive layer structure. The system includes a backing layer, and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase having a composition including 75% to 100% of a polymer or a polymer mixture, and an inner phase that forms dispersed deposits in the outer phase. The inner phase includes rotigotine base and a polymer mixture of at least two hydrophilic polymers. The hydrophilic polymers are selected from the group of polyvinylpyrrolidones having a K-Value of at least 80, polyvinylpyrrolidones having a K-Value of less than 80, copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The polymer mixture in the inner phase is present in an amount sufficient so that it forms a solid solution with the rotigotine base.